The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Effects of abiraterone (ABI) and enzalutamide (ENZA) on cognitive impairment and depressive symptoms in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
 
Sunil Parimi
No Relationships to Disclose
 
Bernhard J. Eigl
Travel, Accommodations, Expenses - Janssen
 
Katherine Sunderland
No Relationships to Disclose
 
Muhammad Zulfiqar
Consulting or Advisory Role - Astellas Pharma; Novartis
 
Daygen L. Finch
No Relationships to Disclose
 
Conrad D. Oja
No Relationships to Disclose
 
Joanna Vergidis
Honoraria - Astellas Pharma; Bayer; Merck; Pfizer; Roche; Sanofi
Consulting or Advisory Role - Astellas Pharma; Genomic Health
 
Leanne Chung-Yan Seto
No Relationships to Disclose
 
Arun Azad
No Relationships to Disclose
 
Martin Gleave
Employment - OncoGenex
Stock and Other Ownership Interests - OncoGenex
Honoraria - Astellas Pharma; Janssen
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Janssen; Oncogenex
Speakers' Bureau - Astellas Pharma; Janssen
Research Funding - Astellas Pharma; Janssen
Travel, Accommodations, Expenses - Amgen
 
Kim N. Chi
Honoraria - Amgen; Astellas Pharma; Janssen; Sanofi
Consulting or Advisory Role - Amgen; Astellas Pharma; Bayer; ESSA; Janssen; Lilly/ImClone; Sanofi; Takeda
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Bayer (Inst); Janssen (Inst); Lilly/ImClone (Inst); Novartis (Inst); Oncogenex (Inst); Sanofi (Inst); Teva (Inst); Tokai Pharmaceuticals (Inst)